MarketCapExport financials
Zealand Pharma A/S (ZEAL)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Zealand Pharma A/S Balance Sheet 2021-2011 | ZEAL
Brief overview of Zealand Pharma A/S's financial position
This overview follows the five latest available annual observations between 2017 and 2021.
Assets rose from 737.2 million DKK to 2.1 billion DKK, a gain of +180.5%, while CAGR was about 29.4%. The balance sheet expanded rapidly.
Asset growth of +180.5% came with a +446% rise in liabilities. Financial leverage became more prominent.
Equity represents 44.9% of assets versus initially. The capital structure appears balanced.
The period ended with net cash: net debt stood at -989.6 million DKK. This supports financial flexibility.
Retained earnings are negative at -3.3 billion DKK. This reduces the formal capital cushion, although large shareholder returns may have contributed.
What the balance sheet shows
Zealand Pharma A/S's balance sheet is broadly resilient, though selected areas require monitoring. The balance between assets, equity and liabilities remains the key issue.
Annual Balance Sheet Zealand Pharma A/S
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-990 M | -830 M | - | -861 M | -453 M | 8.91 M | -106 M | -266 M | -286 M | -359 M | -278 M |
Long Term Debt |
125 M | 116 M | - | - | 133 M | 329 M | 313 M | 267 M | - | - | - |
Long Term Debt Current |
14.9 M | 14.1 M | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
806 M | 177 M | 162 M | - | 133 M | 329 M | 313 M | 267 M | - | - | - |
Total Liabilities |
1.14 B | 533 M | 357 M | 114 M | 209 M | 416 M | 382 M | 344 M | 30.8 M | 30 M | 28.1 M |
Deferred Revenue |
- | 53.2 M | 56.3 M | - | - | - | 2.09 M | 14.4 M | 2.33 M | 5.07 M | 9.28 M |
Retained Earnings |
-3.31 B | -2.29 B | -1.44 B | -894 M | -1.46 B | -1.19 B | 228 M | 230 M | 293 M | 468 M | 418 M |
Total Assets |
2.07 B | 1.76 B | 1.6 B | 1.23 B | 737 M | 695 M | 635 M | 597 M | 347 M | 521 M | 469 M |
Cash and Cash Equivalents |
1.13 B | 960 M | 1.08 B | 861 M | - | - | - | - | - | - | - |
Book Value |
928 M | 1.23 B | 1.24 B | 1.12 B | 528 M | 278 M | 252 M | 253 M | 316 M | 491 M | 441 M |
Total Shareholders Equity |
928 M | 1.23 B | 1.24 B | 1.12 B | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in DKK currency
Quarterly Balance Sheet Zealand Pharma A/S
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | 125 M | - | - | - | 116 M | 119 M | - | - | 78.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 806 M | - | - | - | 177 M | 176 M | - | - | 162 M | - | - | - | - | - | - | - | 133 M | - | - | - | 329 M | - | - | - | 313 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | 1.14 B | - | - | - | 533 M | 469 M | - | - | 357 M | - | - | - | 114 M | - | - | - | 207 M | - | - | - | 416 M | - | - | - | 383 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | - | - | - | -3.31 B | - | - | - | -2.29 B | -1.91 B | - | - | -1.44 B | - | - | - | -872 M | - | - | - | -1.45 B | - | - | - | -1.2 B | - | - | - | -1.04 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
- | - | - | - | 2.07 B | - | - | - | 1.76 B | 2.06 B | - | - | 1.6 B | - | - | - | 1.23 B | - | - | - | 721 M | - | - | - | 683 M | - | - | - | 628 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
- | - | - | - | 1.13 B | - | - | - | 960 M | 1.23 B | - | - | 1.08 B | 1.24 B | - | - | 861 M | - | - | - | 589 M | - | - | - | 323 M | - | - | - | 419 M | - | - | - | 517 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
- | - | - | - | 928 M | - | - | - | 1.23 B | 1.59 B | - | - | 1.24 B | - | - | - | 1.12 B | - | - | - | 515 M | - | - | - | 267 M | - | - | - | 245 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
- | - | - | - | 928 M | - | - | - | 1.23 B | 1.59 B | - | - | 1.24 B | 1.41 B | - | - | 1.12 B | - | - | - | 515 M | - | - | - | 267 M | - | - | - | 245 M | - | - | - | 253 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in DKK currency
Balance Sheet is a fundamental financial report of Zealand Pharma A/S, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
Niderland
France
Israel
Australia
Danmark
Irlanda
